A study into the potential effectiveness of a ketamine in depressed and imminently suicidal patients is to be carried out in the second quarter of 2021, according to the company behind the discovery of the key evidence in its first phase of its study.
Source: investingnews.comPublished on 2021-03-05
Related news
- FactSet To Acquire CUSIP Global Services For $1 . 925 Billion
- Nigeria : Govt Moves to Unmask Owners of Companies With Public Register
- Seelos Therapeutics to Present a Poster on SLS - 002 at the 2021 IASR / AFSP International Summit on Suicide Research
- 21Vianet Wins 5A Green Data Center Ratings and Further Promotes Carbon Reduction
- Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy , Asthma & Immunology Annual Meeting
- The Linux Foundation Announces Registration is Open for Open Source Summit and More Fall Events
- Bronchiolitis : Treatments Are More Expensive / Intensive , But Severity of Illness Hasnt Changed
- SEC introduces new open data centre
- Financial Data Exchange ( FDX ) Reports 22 million Consumer Accounts on FDX API